Sign Out
In order to avoid the emergence of resistant bacteria, bacterial susceptibility should be confirmed and treatment with this drug should be limited to the minimum period required for the eradication of the infection.
The efficacy of this product to methicillin-resistant Staphylococcus aureus (MRSA) has not been proven. Therefore, other drug having a potent anti-MRSA activity should be administered immediately to patients positively infected with MRSA and not showing any improvement of symptoms with this product.
1.5% w/v ophthalmic solution: Use in Children: The safety of this product to low birth weight infants, neonates, infants or children has not been established. No clinical experience with low birth weight infants, neonates or infants. Limited clinical experience with children.
